Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study (Q35119597)

6 August 2017

title

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study (English)

1 reference

cost-effectiveness analysis

6 August 2017

0 references

1 reference

inferred from title

author

Bianca Weinstock-Guttman

6

object named as

B Weinstock-Guttman

1 reference

6 August 2017

K Noyes

1

1 reference

6 August 2017

A Bajorska

2

1 reference

6 August 2017

A Chappel

3

1 reference

6 August 2017

S R Schwid

4

1 reference

6 August 2017

L R Mehta

5

1 reference

6 August 2017

R G Holloway

7

1 reference

6 August 2017

A W Dick

8

1 reference

6 August 2017

language of work or name

English

0 references

publication date

20 July 2011

1 reference

6 August 2017

1 reference

6 August 2017

volume

77

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

355-363

1 reference

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Disability in elderly people with multiple sclerosis: An analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Defining the clinical course of multiple sclerosis: Results of an international survey

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

The MOS 36-ltem Short-Form Health Survey (SF-36)

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3140799

Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21775734

12 December 2020

inferred from PubMed ID database lookup

The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21775734

12 December 2020

inferred from PubMed ID database lookup

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21775734

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1212/WNL.0B013E3182270402

1 reference

6 August 2017

1 reference

6 August 2017

1 reference